Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: CIHR Fellowship

Direct Payment

$150,000.00

Genetic dissection of aneuploidy tolerance

EF 2010-11

Résumé
Our genetic information is stored within DNA and organized into chromosomes. Losses or gains of chromosomes (also called aneuploidy) is a hallmark of most cancer cells. Aneuploidy leads to genetic imbalances and has been linked to the development of malignancies. Although aneuploidy has been shown to hamper cellular fitness, cancer is a disease of malfunctioning cells that multiply in an uncontrolled fashion. This paradox implies that cancer cells have escaped the normal regulatory mechanisms responsible for limiting the proliferation of aneuploid cells. Our understanding of the mechanisms limiting the proliferation of aneuploid cells is sparse and it is thus of pivotal importance to identify the factors responsible for this effect. My research plan involves the systematic inactivation of genes in normal human cells followed by the selection of those genes which, upon inactivation, allow aneuploid cells to multiply and thrive. Subsequently, I will characterize the function of the genes identified in order to understand how human cells sense and respond to the challenges of genetic imbalances. These genes are likely to be inactivated in human tumors. Efficient cancer therapies aim at selectively targeting tumor cells. It is thus essential to characterize the fundamental differences between normal and cancer cells, one of which is the ability of cancer cells to outcompete normal cells despite often being aneuploid. Identifying the mechanisms determining whether or not aneuploid cells multiply and how these processes are deregulated in cancer will offer new avenues to selectively attack cancer cells in future therapeutic approaches. Genes identified in this study might also become useful for their prognostic value, since it is estimated that 90% of human solid tumors become aneuploid.
Programme
CIHR Fellowship
Bénéficiaire
Emplacement
United Kingdom
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
225213
Name
L'Epicier-Sansregret Laurent
Country
United Kingdom
Orgtype
Research Institution
Instname2
Cancer Research
Theme2
Biomedical
Prcname2
Fellowships - Post-PhD
Projecttitle
Genetic dissection of aneuploidy tolerance
Programtype2
Fellowship Programs
Orgnameinp2
Direct Payment
Cihramount2
$150,000
Cihrequipment2
$0
Programname2
CIHR Fellowship
Keyworddelim
Aneuploidy; Cell Cycle Checkpoints; Confocal Microscopy; Genome-Wide Rnai Screen; Genomic Instability; Human Cells; Live-Cell Imaging; P53; Systems Biology; Tumour Suppressor
Abstract
Our genetic information is stored within DNA and organized into chromosomes. Losses or gains of chromosomes (also called aneuploidy) is a hallmark of most cancer cells. Aneuploidy leads to genetic imbalances and has been linked to the development of malignancies. Although aneuploidy has been shown to hamper cellular fitness, cancer is a disease of malfunctioning cells that multiply in an uncontrolled fashion. This paradox implies that cancer cells have escaped the normal regulatory mechanisms responsible for limiting the proliferation of aneuploid cells. Our understanding of the mechanisms limiting the proliferation of aneuploid cells is sparse and it is thus of pivotal importance to identify the factors responsible for this effect. My research plan involves the systematic inactivation of genes in normal human cells followed by the selection of those genes which, upon inactivation, allow aneuploid cells to multiply and thrive. Subsequently, I will characterize the function of the genes identified in order to understand how human cells sense and respond to the challenges of genetic imbalances. These genes are likely to be inactivated in human tumors. Efficient cancer therapies aim at selectively targeting tumor cells. It is thus essential to characterize the fundamental differences between normal and cancer cells, one of which is the ability of cancer cells to outcompete normal cells despite often being aneuploid. Identifying the mechanisms determining whether or not aneuploid cells multiply and how these processes are deregulated in cancer will offer new avenues to selectively attack cancer cells in future therapeutic approaches. Genes identified in this study might also become useful for their prognostic value, since it is estimated that 90% of human solid tumors become aneuploid.
Competitiondate
201102
Approvedterm2
3 yrs 0 mth
Pinamesdelim
L'Epicier-Sansregret, Laurent
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $150,000~ $0~